Below, we’ve compiled answers to some of the most common questions we’ve received about these investigations, the science behind the concerns, and next steps for affected individuals.
What is cutaneous T-cell lymphoma (CTCL)?
CTCL is a rare cancer that starts in the body’s immune system but shows up on the skin. It can look like eczema at first, with red, scaly, itchy patches. Over time, it can spread, forming thicker lesions, affecting the lymph nodes, and, in advanced cases, spreading to other organs. Because the early symptoms mimic common skin conditions, CTCL is often misdiagnosed or diagnosed late.
How is Dupixent® connected to CTCL?
Studies published in 2024 and 2025 have shown that patients taking dupilumab (Dupixent®) are significantly more likely to develop CTCL compared to those who are not. Doctors believe Dupixent® may unmask undiagnosed CTCL by suppressing eczema-like symptoms, making the cancer more visible only after it has progressed. Other research suggests the drug may play a role in accelerating the disease. The manufacturers of Dupixent®, Sanofi and Regeneron, failed to communicate these risks to patients or prescribers.
What warning signs should families watch for?
If Dupixent® is not improving skin symptoms, or if the rash seems to worsen, spread, or change in appearance, this can be a red flag. Other warning signs include unexplained itching, new nodules or lesions, swollen lymph nodes, or weight loss. Families should ask for a biopsy and further testing if symptoms do not improve.
Does scientific evidence support a connection between CTCL and Dupixent®?
A growing number of peer‑reviewed studies have looked closely at the connection between Dupixent® and CTCL.
- One 2024 study led by Hasan and colleagues found that patients with atopic dermatitis who were treated with Dupixent® had more than a threefold higher risk of developing CTCL, twofold after adjusting for age, sex, and certain other factors.
- Another 2024 analysis by Mandel et al. using TriNetX data reported a similarly elevated risk when comparing Dupixent® users to non‑users.
- In 2025, Ma and colleagues examined asthma patients who started Dupixent® and found that the risk of CTCL was more than four times higher compared to those treated with other asthma drugs. The risk was even greater for certain T‑ and NK‑cell lymphomas after longer use.
- Earlier reports, including a 2019 article in the Journal of the American Academy of Dermatology, documented cases where CTCL symptoms accelerated while patients were on Dupixent®.
- Additional case reports continue to warn that the drug may unmask or worsen hidden lymphomas mistaken for eczema.
Who can file a Dupixent® claim?
You may be eligible if you or a loved one were prescribed Dupixent® and later diagnosed with CTCL. Families who lost a loved one may also pursue a wrongful death claim. To support your claim, you will need to show medical records showing Dupixent® use, the timing of symptoms and diagnosis, and whether cancer was discovered after treatment began. Our Dupixent® attorneys can help you gather this information.
What kinds of compensation are available?
Patients and families may be able to recover the costs of past and future medical treatment, lost income, and reduced earning capacity. Compensation may also be available for the pain, suffering, and emotional distress caused by the diagnosis. If your loved one died as a result of their CTCL, you may be able to seek damages for wrongful death, including loss of companionship and financial support.
Do these cases always go to trial?
Not always. Some claims resolve through negotiated settlements. But when drug manufacturers deny responsibility, litigation may be necessary. At Morris James, we are trial-ready and tested. If going to court is what it takes to protect our clients, we are prepared to stand before a jury.
How long do I have to file a claim?
Every state has its own statute of limitations, which sets a filing deadline. In many cases, claims should typically be filed within two years of the injury or diagnosis. However, because these deadlines vary, it is critical to speak with a lawyer as soon as possible to avoid losing your right to bring a claim.
If Dupixent® (dupilumab) is not improving skin symptoms, or if the rash seems to worsen, spread, or change in appearance, this can be a red flag. Other warning signs include unexplained itching, new nodules or lesions, swollen lymph nodes, or weight loss. Families should ask for a biopsy and further testing if symptoms do not improve.
